

# Prudence A Francis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5845250/publications.pdf>

Version: 2024-02-01

121  
papers

13,436  
citations

38660

50  
h-index

22764

112  
g-index

122  
all docs

122  
docs citations

122  
times ranked

13409  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , 2013, 31, 860-867.	0.8	1,342
2	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). <i>Annals of Oncology</i> , 2018, 29, 1634-1657.	0.6	891
3	3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). <i>Annals of Oncology</i> , 2017, 28, 16-33.	0.6	865
4	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017, 28, 1700-1712.	0.6	844
5	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	13.9	621
6	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 436-446.	13.9	588
7	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
8	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 923-932.	13.9	452
9	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 122-137.	13.9	448
10	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Annals of Oncology</i> , 2014, 25, 1871-1888.	0.6	402
11	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
12	Strategies for the discovery and development of therapies for metastatic breast cancer. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 479-497.	21.5	310
13	1st International consensus guidelines for advanced breast cancer (ABC 1). <i>Breast</i> , 2012, 21, 242-252.	0.9	291
14	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Breast</i> , 2014, 23, 489-502.	0.9	269
15	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37-298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452.	6.3	260
16	Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel. <i>Gynecologic Oncology</i> , 1996, 63, 89-93.	0.6	238
17	Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 1994, 12, 1232-1237.	0.8	211
18	Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1994, 12, 2301-2308.	0.8	188

#	ARTICLE	IF	CITATIONS
19	Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.. Journal of Clinical Oncology, 1995, 13, 2961-2967.	0.8	175
20	3rd ESOâ€“ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, 244-259.	0.9	171
21	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of Clinical Oncology, 2016, 34, 2221-2231.	0.8	148
22	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€“864 women in seven randomised trials. Lancet Oncology, The, 2021, 22, 1139-1150.	5.1	147
23	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncology, The, 2015, 16, 848-858.	5.1	145
24	Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial. Journal of the National Cancer Institute, 2008, 100, 121-133.	3.0	140
25	Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.. Journal of Clinical Oncology, 1996, 14, 1877-1884.	0.8	138
26	Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. Journal of the National Cancer Institute, 2002, 94, 1054-1065.	3.0	138
27	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Research and Treatment, 2010, 119, 145-153.	1.1	137
28	Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4498-4504.	0.8	131
29	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program â€“CASCADEâ€“. PLoS Medicine, 2016, 13, e1002204.	3.9	119
30	Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer, 1995, 75, 968-972.	2.0	113
31	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	2.3	112
32	Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptorâ€“Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. Journal of Clinical Oncology, 2016, 34, 1584-1593.	0.8	108
33	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncology, The, 2022, 23, 382-392.	5.1	107
34	Phase II trials of docetaxel (taxotereÂ®) in advanced ovarian cancerâ€“an updated overview. European Journal of Cancer, 1997, 33, 2167-2170.	1.3	104
35	Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Journal of Clinical Oncology, 2017, 35, 3113-3122.	0.8	101
36	Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. Journal of Clinical Oncology, 2016, 34, 1601-1610.	0.8	100

#	ARTICLE	IF	CITATIONS
37	A Prospective Cohort Study of the Effects of Adjuvant Breast Cancer Chemotherapy on Taste Function, Food Liking, Appetite and Associated Nutritional Outcomes. <i>PLoS ONE</i> , 2014, 9, e103512.	1.1	100
38	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020, 38, 1293-1303.	0.8	93
39	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
40	Impact of a novel nurse-led prechemotherapy education intervention (ChemoEd) on patient distress, symptom burden, and treatment-related information and support needs: results from a randomised, controlled trial. <i>Annals of Oncology</i> , 2012, 23, 222-231.	0.6	88
41	Constitutive Variability in the Pharmacokinetics of the Natural Retinoid, All-trans-Retinoic Acid, and Its Modulation by Ketoconazole. <i>Journal of the National Cancer Institute</i> , 1993, 85, 1921-1926.	3.0	80
42	International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)â€™MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. <i>Breast</i> , 2013, 22, 203-210.	0.9	77
43	Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. <i>Breast</i> , 2013, 22, 1094-1100.	0.9	73
44	Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. <i>Breast</i> , 2011, 20, 111-118.	0.9	71
45	Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. <i>Journal of the National Cancer Institute</i> , 2019, 111, 210-213.	3.0	70
46	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	9.4	66
47	Research needs in breast cancer. <i>Annals of Oncology</i> , 2017, 28, 208-217.	0.6	64
48	Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. <i>Annals of Oncology</i> , 2017, 28, 2225-2232.	0.6	56
49	Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. <i>Annals of Oncology</i> , 2009, 20, 1813-1817.	0.6	53
50	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <i>Breast Cancer Research</i> , 2012, 14, R70.	2.2	52
51	Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. <i>Annals of Oncology</i> , 2008, 19, 1231-1241.	0.6	50
52	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 316-324.	0.4	50
53	Ovarian cancer: patterns of care in Victoria during 1993â€™1995. <i>Medical Journal of Australia</i> , 2002, 177, 11-16.	0.8	39
54	Metastatic breast cancer in elderly patients. <i>Breast</i> , 2011, 20, S20-S21.	0.9	38

#	ARTICLE	IF	CITATIONS
55	Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 956-964.	2.9	38
56	Paclitaxel (Taxol) and Docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. <i>Lung Cancer</i> , 1995, 12, S163-S172.	0.9	37
57	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 275-286.	1.1	37
58	Supportive care of women with breast cancer: key concerns and practical solutions. <i>Medical Journal of Australia</i> , 2016, 205, 471-475.	0.8	36
59	Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. <i>Journal of Clinical Oncology</i> , 2020, 38, 2883-2891.	0.8	35
60	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1672-1673.	13.9	34
61	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33
62	Final 10-year results of the Breast International Group 2019 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
63	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2020, 22, 91.	2.2	32
64	Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 483-488.	1.1	26
65	Words Matter: Distinguishing "Personalized Medicine" and "Biologically Personalized Therapeutics". <i>Journal of the National Cancer Institute</i> , 2014, 106, dju321-dju321.	3.0	26
66	<i>Legionella pneumophila</i> lung abscess associated with immune suppression. <i>Internal Medicine Journal</i> , 2011, 41, 715-721.	0.5	22
67	Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1357-1359.	13.9	22
68	Overall survival benefit for sequential doxorubicin+docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer: 8-year results of the Breast International Group 02-98 phase III trial. <i>Annals of Oncology</i> , 2013, 24, 1203-1211.	0.6	21
69	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 347-359.	1.1	19
70	Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 125-135.	1.1	18
71	Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial. <i>Annals of Oncology</i> , 2008, 19, 1837-1841.	0.6	17
72	Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor+Positive Early Breast Cancer: Lights and Shadows. <i>Journal of Clinical Oncology</i> , 2019, 37, 862-866.	0.8	17

#	ARTICLE	IF	CITATIONS
73	Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. <i>British Journal of Cancer</i> , 2019, 120, 279-285.	2.9	17
74	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. <i>Cancer Discovery</i> , 2022, 12, 2058-2073.	7.7	16
75	Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure. <i>Bone</i> , 2017, 103, 131-135.	1.4	15
76	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. <i>Journal of Clinical Oncology</i> , 2018, 36, 503-503.	0.8	15
77	Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study. <i>Annals of Oncology</i> , 1999, 10, 479-481.	0.6	14
78	Systemic treatment of HER2-positive metastatic breast cancer: A systematic review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 1-14.	0.7	14
79	Are SOFT and TEXT results practice changing and how?. <i>Breast</i> , 2016, 27, 122-125.	0.9	14
80	Diethyldithiocarbamate chemoprotection of carboplatin-induced hematological toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 1993, 119, 360-362.	1.2	13
81	Optimal adjuvant therapy for very young breast cancer patients. <i>Breast</i> , 2011, 20, 297-302.	0.9	13
82	Light-enhanced cognitive behavioural therapy for sleep and fatigue: study protocol for a randomised controlled trial during chemotherapy for breast cancer. <i>Trials</i> , 2020, 21, 295.	0.7	13
83	Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e47-e61.	1.8	12
84	Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. <i>Bone Marrow Transplantation</i> , 1999, 23, 427-435.	1.3	11
85	Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy. <i>Cytotherapy</i> , 2002, 4, 137-145.	0.3	11
86	Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	11
87	Taxanes as adjuvant for breast cancer. <i>Lancet, The</i> , 2000, 356, 507-508.	6.3	10
88	Light enhanced cognitive behavioral therapy for insomnia and fatigue during chemotherapy for breast cancer: a randomized controlled trial. <i>Sleep</i> , 2022, 45, .	0.6	10
89	Surprised by Hope. <i>Journal of Clinical Oncology</i> , 2008, 26, 6001-6002.	0.8	9
90	Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. <i>Breast</i> , 2011, 20, 101-110.	0.9	9

#	ARTICLE	IF	CITATIONS
91	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018, 52, 424-432.	1.4	9
92	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 67.	2.3	8
93	Estrogen levels in premenopausal (premenopausal) patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy. <i>Journal of Clinical Oncology</i> , 2014, 32, 585-585.	0.8	6
94	Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, LBA505-LBA505.	0.8	6
95	Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 602-602.	0.8	6
96	Neoadjuvant chemotherapy with sequential anthracycline+docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). <i>Breast</i> , 2014, 23, 142-151.	0.9	5
97	Adjuvant endocrine therapy for premenopausal women: Type and duration. <i>Breast</i> , 2017, 34, S108-S111.	0.9	5
98	Implementation of a Multidisciplinary Model of Care for Women With Metastatic Breast Cancer: Challenges and Lessons Learned. <i>Clinical Breast Cancer</i> , 2019, 19, e327-e336.	1.1	5
99	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
100	Activity and toxicity of docetaxel (Taxotere®) in women with previously treated metastatic breast cancer. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 40-44.	0.5	3
101	A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. <i>Investigational New Drugs</i> , 1999, 17, 73-80.	1.2	3
102	Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC). <i>Journal of Clinical Oncology</i> , 2014, 32, 557-557.	0.8	3
103	High-Intensity Chemotherapy with Hematopoietic Support in Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 378-388.	1.8	2
104	Central nervous system metastases in women with HER-2 positive metastatic breast cancer after treatment with trastuzumab. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 50-56.	0.7	2
105	Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT). , 2015, , .		2
106	Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po. , 2015, , .		2
107	Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. <i>Breast</i> , 2022, , .	0.9	2
108	Systemic treatment of <sc>HER</sc>2+ metastatic breast cancer: Clinical conundrums and future perspectives. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 15-25.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Dual HER2 Blockade. <i>Breast Care</i> , 2017, 12, 345-349.	0.8	1
110	Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration. <i>Breast</i> , 2019, 48, S85-S88.	0.9	1
111	Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer. <i>European Journal of Cancer</i> , 2020, 136, 206.	1.3	1
112	Feasibility of implementing a pharmacist-led DPYD gene testing service for patients commencing 5-fluorouracil (5FU) or capecitabine.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18644-e18644.	0.8	1
113	Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14098-e14098.	0.8	1
114	Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial. , 2015, , .		1
115	IN27 ADVANCED BREAST CANCER: IS THERE AN OPTIMAL SEQUENCE OF SYSTEMIC ANTICANCER AGENTS?. <i>Breast</i> , 2015, 24, S31.	0.9	0
116	Reply to F. Tomao et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 4189-4190.	0.8	0
117	Maintenance Therapy (Chemotherapy, Endocrine Therapy, Biologics). <i>Breast</i> , 2017, 36, S23-S24.	0.9	0
118	In Reply to Belkacemi and Tsoutsou. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 467-468.	0.4	0
119	Young Patients with Breast Cancer. <i>Cancer Treatment and Research</i> , 2009, 151, 291-298.	0.2	0
120	Abstract P5-19-03: What are the barriers to assessment of ovarian toxicity in breast cancer clinical trials?. <i>Cancer Research</i> , 2022, 82, P5-19-03-P5-19-03.	0.4	0
121	Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT.. <i>Journal of Clinical Oncology</i> , 2022, 40, 508-508.	0.8	0